We expect the revenue to grow at 15.8% CAGR during FY19-21E while EBITDA to grow at 15% CAGR. EBITDA margin is expected to stabilize around 15% levels by FY21E. Considering the healthy order book, proven execution capabilities, revenue visibilitycoupled with strong financials, we re-iterate a “BUY” rating with a target price of Rs. 300 based on a SoTP valuation.
HGINFRA continues to report steady performance mainly led by continuous traction in execution. We still expect its earning to clock 29% CAGR in next 2 years. At CMP, the stock trades at 9.0x of FY20 and 7.4x of FY21 earnings with >20% return ratio. We believe improvement in cash generation will be the key catalyst for re-rating. Keeping our estimates unchanged, we maintain BUY recommendation on the stock with an unrevised Target Price of Rs385 (15x of 1-Yr Fwd. EPS).
While impact of high base is visible in the quarterly performance, we believe commencement of new order wins will further aid the Company to register a healthy growth, going ahead. We expect HGINFRA’s earning to clock 31% CAGR in next 2 years. Current valuation at 10.4x of FY20 and 8.4x of FY21 earnings with >20% return ratio and <2x book value undoubtedly appear to be attractive. We continue to maintain our BUY recommendation on the stock with a revised Target Price of Rs395 (15x of FY20 EPS).
We expect revenue/ Adj. PAT CAGR of 23.9%/ 30.3% over FY19-21E. HGINFRA looks attractive at 11.3x/ 9.1x FY20E/ FY21E EPS, hence we maintain BUY, with a SOTP of Rs 456 (13x FY21E EPS) and 1xFY21E P/B for HAM equity investments.